parkinson's disease

Glutathione Articles - Parkinson's Disease

Sechi G; Deledda MG; Bua G; Satta WM; Deiana GA; Pes GM; Rosati G, Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neurophyschopharmacol Biol Psychiatry, 20(7); 1159-70 1996 Oct.
Johannsen P; Velander G; Mai J; Thorling EB; Dupont E, Glutathione peroxidase in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry, 54 (8); 679-82 1991 Aug.
Spina MB; Cohen G, Dopamine turnover and glutathione oxidation: implications for Parkinson’s disease. Proc Natl Acad Sci U S A, 86(4); 1398-400 1989 Feb.
Di Monte DA; Chan P; Sandy MS, Glutathione in Parkinson’s disease: A link between oxidative stress and mitochondrial damage? Ann Neurol. 1992 Suppl (32); S111-5.
Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD, Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol, 36(3); 348-55 1994 Sep.
Merad-Boudia M; Santiard-Baron D; Saill’e C; Ceballos-Picot I, Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: Relevance to Parkinson’s disease. Biochem Pharmacol, 56(5):645-55 1998 Sep 1.
Perry TL; Yong V, Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in substantia nigra of patients. Neurosci Lett 1986; 67:269-74.
Perry TL; Hansen S; Jones K, Brain amino acids and glutathione in progressive supranuclear palsy. Neurology 1988; 38:943-6.
Riederer P; Sofic E; Rausch W; Schmidt B; Reynolds G; Jellinger K; Youdim M, Transition metals, ferrentin, glutathione, and ascorbic acid in pakinsonian brains. J Neurochem 1989; 52:515-520.
Pearce R; Owen S; Daniel S; Jenner P; Marsden C, Alterations in the distribution of glutathione in substantia nigra in Parkinson's disease. J Neural Transm 1997; 104:661-77.
Jenner P; Dexter D; Sian J; Schapira A; Marsden C; Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease. Ann Neurol 1992; 32:S82-S87.
Perry TL; Godin D V; Hansen S; Jones K, Parkinson's Disease: a disorder due to nigral cell glutathione deficiency. Neurosci Lett 1982; 33:300-10.
Jha N; Jurma O; Lalli G; Liu X; Pettus EH, et al, Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity. J Biol Chem. 2000 Aug; Vol 275(34):26096-101.
Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P and Marsden CD. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol. 1994 Sep;36(3):348-55.
Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, Rane A, Nicholls DG, Choi J, and Andersen JK. Glutathione Depletion Leads to Symptoms of Parkinson's Disease in Mice. J Neurosci. 2007 Dec 19;27(51):13997-4006.
Jenner P, Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl. 1993;146:6-13.
S. Canals, M. J. Casarejos, S. de Bernardo, E. RodrõÂguez-MartõÂn and M. A. Mena, Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures: implications for Parkinson's disease. J Neurochem. (2001) 79, 1183-1195.
Jenner P, What process causes nigral cell death in Parkinson's disease? Neurol Clin. 1992 May 10(2):387-403.

Video Testimony of Glutathione Use with Parkinson's Patients

Watch a video produced by Dr. David Perlmutter showing the before and after effects of IV glutathione on Parkinson's patients. > See Benefits of Glutathione

If you would like us to send you abstracts of any of the articles listed above, please contact us by phone or e-mail:

Caron Coats

Toll Free:
Tel: 800-227-2627
Fax: 800-369-0302

Local:
Tel: 205-879-6551
Fax: 205-871-2568

Email:
ccoats@wellnesshealth.com